Assurance de qualité pour le cancer rectal – phase 2 ...

KCE Reports 81 PROCARE – phase 2 155APPENDIX 5: AVAILABILITY OF QUALITY INDICATORS IN OTHER COUNTRIESBavaria Burgundy North NL SW SPAIN UK DK NOverall 5-year survival by stage Yes Yes Yes Yes Yes Yes Yes YesDisease-specific survival by stage at 2 yr, 5 yr Yes Yes No * Yes Yes Yes (death Yes Nocertif)Proportion of patients with local recurrence by stage at 2 No Yes No * Yes Yes No No Yesyr, 5 yrProportion of patients discussed at a multidisciplinary No Yes No * Yes Yes No No Noteam (MDT) meetingProportion of patients with a documented distance from No Yes No * Yes Yes No Yes Yesthe anal vergeProportion of patients in whom a CT of the liver and No No * Yes Yes No Yes Yesthorax was performed before any treatmentProportion of patients in whom a CEA was detrmined No No * No No No No Yesbefore any treatmentProportion of patients undergoing preoperative complete No No * Yes No No No Nolarge bowel-imagingProportion of patients in whom a TRUS and pelvic CTand/or pelvic MRI was performed before any treatmentNo Yes No * Yes Yes No Yes Yes after2001Proportion of patients with a reported cCRM No No * Yes Yes Yes Yes Yes(subsets)Pretreatment cStage (TNM) Yes Yes Yes Yes No Yes YesTime between initial diagnosis and first treatment No No Yes No Yes Yes Yes YesProportion of stage II-III patients that received a short No Not used No * Yes Yes Yes No Not usedcourse of neoadjuvant pelvic RTProportion of stage II-III patients that received a long No Yes No * Yes Yes Yes No Yescourse of neoadjuvant pelvic RTProportion of stage II-III patients that received neoadjuvantchemoradiation with a regimen containing 5-FUNo Yes Yes Yes Yes No No Yes